AR020084A1 - Pestivirus atenuados - Google Patents

Pestivirus atenuados

Info

Publication number
AR020084A1
AR020084A1 ARP990102650A ARP990102650A AR020084A1 AR 020084 A1 AR020084 A1 AR 020084A1 AR P990102650 A ARP990102650 A AR P990102650A AR P990102650 A ARP990102650 A AR P990102650A AR 020084 A1 AR020084 A1 AR 020084A1
Authority
AR
Argentina
Prior art keywords
pestivirus
glycoprotein
vaccine
pestiviruses
residing
Prior art date
Application number
ARP990102650A
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of AR020084A1 publication Critical patent/AR020084A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24361—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pestivirus específicamente atenuados y marcados en forma detectable para uso como vacunas atenuadas vivas con una elevada con una elevada eficacia para lainduccion de inmunidad que también se pueden distinguir de pestivirus patogenos procedentes delcampo. Una vacuna viva que comprende un pestivirus, en la quela actividad de RNasa que reside en la glicoproteina E(RNS) está inactivada. Un pestivirus para una vacuna, en el que la actividad de RNasa que reside en laglicoproteína E(RNS) estáinactiv ada por deleciones y/o mutaciones de al menos un aminoácido de dicha glicoproteína, con la condicion de que los aminoácidos enla posicion 297 y/o 346 de dicha proteína no sean lisina. Un ácido nucleico que codifica una glicoproteína que seexpresa en un pestivirus, en el que laactividad de RNasa que reside en dicha glicoproteína ERNS está inactivada por deleciones y/o mutaciones de al menos un aminoácido de dicha glicoproteína, conla condicion de que los aminoácidos en la posicion 297y/o 346 de dicha proteína no sean lisina. El empleo de ácidos nucleicos para preparar vacunas denucleotidos y/o vectores. Una composicion farmacéutica que contiene una vacuna, y/o un pestivirus, y/o una secuencia de nucleotidos. Un método paraatenuarpestiviru s destinados a la vacuna, un método para producir una vacuna específicamente atenuada, un método para marcar de forma detectable pestivirus, un métodopara la profilaxis y el tratamiento de infecciones por pestivirus, unprocedimiento para la preparac ion de pestivirus específicamente atenuados y un métodopara distinguir animales infestados por pestivirus de animales vacunados con un pestivirus específicamente atenuado. El uso de la y de la composicionfarmacéuticapara la profilaxis y el tratamien to de infecciones por pestivirus en animales. El uso de un pestivirus y/o una secuencia de nucleotidospara preparar una vacuna o una composicion farmacéutica.
ARP990102650A 1998-06-05 1999-06-04 Pestivirus atenuados AR020084A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98110356A EP0965639A1 (en) 1998-06-05 1998-06-05 Attenuated pestiviruses

Publications (1)

Publication Number Publication Date
AR020084A1 true AR020084A1 (es) 2002-04-10

Family

ID=8232074

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP990102650A AR020084A1 (es) 1998-06-05 1999-06-04 Pestivirus atenuados
ARP090101843A AR071881A2 (es) 1998-06-05 2009-05-22 Pestivirus atenuados
ARP090101842A AR071880A2 (es) 1998-06-05 2009-05-22 Metodo para marcar de forma detectable pestivirus

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP090101843A AR071881A2 (es) 1998-06-05 2009-05-22 Pestivirus atenuados
ARP090101842A AR071880A2 (es) 1998-06-05 2009-05-22 Metodo para marcar de forma detectable pestivirus

Country Status (23)

Country Link
EP (5) EP0965639A1 (es)
JP (3) JP4632540B2 (es)
KR (1) KR100637940B1 (es)
CN (2) CN100374563C (es)
AR (3) AR020084A1 (es)
AT (3) ATE316380T1 (es)
AU (1) AU769823C (es)
BR (2) BRPI9917787B1 (es)
CA (1) CA2330241C (es)
CO (1) CO5050392A1 (es)
CZ (3) CZ301570B6 (es)
DE (3) DE69928700T2 (es)
DK (3) DK1084251T3 (es)
ES (3) ES2235488T3 (es)
HU (3) HU228469B1 (es)
NZ (1) NZ509228A (es)
PE (1) PE20000552A1 (es)
PL (2) PL202161B1 (es)
PT (2) PT1084251E (es)
SI (3) SI1084251T1 (es)
SK (3) SK287626B6 (es)
TR (3) TR200003622T2 (es)
WO (1) WO1999064604A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7179473B2 (en) 1998-06-05 2007-02-20 Boehringer Ingelheim Vetmedica Gmbh Attenuated pestiviruses
EP1104676A1 (en) * 1999-11-30 2001-06-06 Boehringer Ingelheim Vetmedica Gmbh Safe attenuated bovine viral diarrhea viruses for use in pregnant cows
DE60118456T2 (de) 2000-04-21 2006-08-24 Akzo Nobel N.V. Pestvirus Mutanten und diese enthaltende Impfstoffe
US7135561B2 (en) 2001-09-06 2006-11-14 Boehringer Ingelheim Vetmedica Gmbh Infectious bovine viral diarrhea virus clone
UY29915A1 (es) * 2005-11-15 2007-06-29 Boehringer Ingelheim Vetmed Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina
AR069087A1 (es) 2007-10-29 2009-12-30 Boehringer Ingelheim Vetmed Cepa bacteriana de m. bovis atenuada avirulenta obtenida por pases, vacuna de micoplasma boris y metodos de uso de la misma
UY31930A (es) 2008-06-25 2010-01-29 Boheringer Ingelheim Pharma Kg Pestivirus atenuados recombinantes, en particular a csfv, bvdv o bdv atenuado recombinante
EP2362780B1 (en) 2008-10-31 2019-12-25 Boehringer Ingelheim Animal Health USA Inc. Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
US8846054B2 (en) 2009-01-09 2014-09-30 Boehringer Ingelheim Vetmedica, Inc. Method of treating pregnant cows and/or heifers
UY32570A (es) 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada
CN101915837B (zh) * 2010-07-28 2013-07-03 中国兽医药品监察所 一种猪瘟兔化弱毒活疫苗效力检验方法
ES2606605T3 (es) 2010-09-21 2017-03-24 Intervet International B.V. Vacuna para el BVDV
CN103882051B (zh) * 2014-03-20 2016-04-06 北京市农林科学院 一种检测猪瘟病毒抗体的elisa方法及检测试剂盒
DK3146042T3 (da) * 2014-05-23 2019-09-30 Boehringer Ingelheim Vetmedica Gmbh Rekombinant klassisk svinepestvirus (CSFV) med substitution i E2-proteinets TAV-epitop
PH12021552641A1 (en) * 2019-04-18 2022-07-18 Boehringer Ingelheim Vetmedica China Co Ltd Recombinant classical swine fever virus

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE342996T1 (de) * 1986-01-27 2006-11-15 Schering Plough Ltd Attenuierte herpesviren, herpesviren die eine aminosäuresequenz kodierende fremde dna enthalten,und diese enthaltende impfstoffe

Also Published As

Publication number Publication date
CA2330241A1 (en) 1999-12-16
SI1084251T1 (en) 2005-08-31
HU228468B1 (en) 2013-03-28
BR9911619B1 (pt) 2013-11-12
TR200103664T2 (tr) 2002-06-21
EP1203813A3 (en) 2004-02-04
SK287626B6 (sk) 2011-04-05
HUP0102707A2 (hu) 2001-11-28
PL348019A1 (en) 2002-05-06
KR100637940B1 (ko) 2006-10-23
PL202509B1 (pl) 2009-06-30
ATE286131T1 (de) 2005-01-15
EP1203812A2 (en) 2002-05-08
AU769823C (en) 2004-11-25
DK1084251T3 (da) 2005-04-11
CZ301494B6 (cs) 2010-03-24
PT1203813E (pt) 2006-06-30
ATE311193T1 (de) 2005-12-15
PE20000552A1 (es) 2000-07-14
CO5050392A1 (es) 2001-06-27
CZ20004533A3 (cs) 2001-07-11
EP0965639A1 (en) 1999-12-22
PL202161B1 (pl) 2009-06-30
TR200103666T2 (tr) 2002-03-21
BR9911619A (pt) 2001-10-02
EP1614423A3 (en) 2008-01-30
AR071881A2 (es) 2010-07-21
JP4632540B2 (ja) 2011-02-16
DE69929544T2 (de) 2006-07-20
EP1084251B1 (en) 2004-12-29
DE69928700T2 (de) 2006-06-22
DE69928700D1 (de) 2006-01-05
ES2235488T3 (es) 2005-07-01
CZ301569B6 (cs) 2010-04-21
WO1999064604A2 (en) 1999-12-16
HUP0102707A3 (en) 2008-04-28
ES2253457T3 (es) 2006-06-01
EP1203812B1 (en) 2005-11-30
EP1203813B1 (en) 2006-01-25
SK287625B6 (sk) 2011-04-05
TR200003622T2 (tr) 2001-06-21
EP1203812A3 (en) 2004-02-04
AU769823B2 (en) 2004-02-05
PT1084251E (pt) 2005-03-31
AR071880A2 (es) 2010-07-21
JP2002517250A (ja) 2002-06-18
SK18232000A3 (sk) 2001-05-10
JP2010259445A (ja) 2010-11-18
CN1304452A (zh) 2001-07-18
SK287014B6 (sk) 2009-09-07
WO1999064604A3 (en) 2000-01-27
SI1203813T1 (sl) 2006-06-30
SI1203812T1 (sl) 2006-04-30
ES2257476T3 (es) 2006-08-01
CZ301570B6 (cs) 2010-04-21
JP2013099357A (ja) 2013-05-23
DK1203813T3 (da) 2006-05-22
CA2330241C (en) 2010-09-21
BRPI9917787B1 (pt) 2016-09-06
CN100374563C (zh) 2008-03-12
JP5755265B2 (ja) 2015-07-29
CN101085346A (zh) 2007-12-12
DE69922953T2 (de) 2005-05-19
DE69922953D1 (de) 2005-02-03
KR20010071406A (ko) 2001-07-28
HU228471B1 (en) 2013-03-28
NZ509228A (en) 2003-12-19
ATE316380T1 (de) 2006-02-15
JP5247770B2 (ja) 2013-07-24
EP1084251A2 (en) 2001-03-21
EP1614423A2 (en) 2006-01-11
HU228469B1 (en) 2013-03-28
AU4369299A (en) 1999-12-30
EP1203813A2 (en) 2002-05-08
DK1203812T3 (da) 2006-04-10
DE69929544D1 (de) 2006-04-13

Similar Documents

Publication Publication Date Title
UY39060A (es) Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2
AR035586A1 (es) Composicion de vacuna, equipo, metodos para incrementar la respuesta inmune, uso de un derivado de 1h-imidazo(4,5-c)quinolin-4-amina en la fabricacion de un medicamento, y combinacion de componentes para la administracion separada, secuencial o concomitante para el uso en la vacunacion de adn
NO20004972L (no) Derivater av pneumokokkale kolinbindende proteiner for vaksiner
PE20230171A1 (es) Vacunas contra el coronavirus y metodos de uso
AR020134A1 (es) Antigenos inmunologicos contra el virus herpes simplex y metodos para el uso de los mismos
ES2070266T3 (es) Vacuna contra la infeccion por escherichia coli.
CY1107188T1 (el) Εμβολιο ε. coli πτηνου για την προστασια εναντι κολοβακτηριωσης
WO2023094713A3 (en) Coronavirus vaccine
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
AR109538A1 (es) Vacuna contra la gripe porcina
WO2022103929A3 (en) Nucleic acids, proteins, and vaccines of sars-cov-2
ECSP024257A (es) Proteinas antigenas del virus de la enfermedad de la mancha blanca en el camaron y usos de las mismas
BR0006291A (pt) Bactéria do gênero salmonella, vacina para aproteção de animais contra a salmonelose, uso deuma bactéria, e, processo para a preparação deuma vacina
AR123244A1 (es) Vacuna de salmonella para el tratamiento de coronavirus
PE20000552A1 (es) Pestivirus atenuados
FR2828405B1 (fr) Vaccin anti-coronavirus
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
ATE252153T1 (de) Rekombinanter birnavirusimpfstoff
ES2063897T5 (es) Vacuna contra el virus del colera porcino y diagnostico.
WO2006046017A3 (en) Vaccine and nucleic acids capable of protecting poultry against colonisation by campylobacter
ATE201446T1 (de) Impfstoff gegen geflügelkokzidose
ES2059305T3 (es) Proteina del virus de la seudorrabia.
AR027443A1 (es) MUTANTES DE EHV gM-NEGATIVOS
RU2339692C2 (ru) Туберкулезные вакцины, содержащие рекомбинантные штаммы бцж, экспрессирующие аланиндегидрогеназу, сериндегидратазу и/или глютаминсинтетазу

Legal Events

Date Code Title Description
FG Grant, registration